You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 百濟神州(6160.HK)創7個月新高 百澤安上市申請獲美受理 用於食管鱗狀細胞癌
格隆匯 09-15 15:16
格隆匯9月15日丨百濟神州(6160.HK)漲逾4%,暫錄四連漲,報229港元創近7個月新高,總市值2770億港元。百濟神州本週一發佈公吿宣佈,百澤安(替雷麗珠單抗注射液)針對食管鱗狀細胞癌的新藥上市申請獲美國食品藥品監督管理局(FDA)受理,用於治療既往經系統治療後不可切除、複發性局部晚期或轉移性食管鱗狀細胞癌(ESCC)患者。同一天,百濟神州的BGB-A445注射液首次在國內申報臨牀。這是一款OX40激動劑抗體。百濟此前已在國外啟動了該藥的I期臨牀。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account